Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient – death of a dogma from analysis of therapeutic studies?

References

• Loria P, Adinolfi LE, Bellentani S et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig. Liver Dis.42, 272–282 (2010).
   PubMedGoogle Scholar
• Caldwell S, Ikura Y, Dias D et al. Hepatocellular ballooning in NASH. J. Hepatol.53, 719–723 (2010).
   PubMed Web of Science ®Google Scholar
• Caldwell SH, Swerdlow RH, Khan EM et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol.31, 430–434 (1999).
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology120, 1183–1192 (2001).
   PubMed Web of Science ®Google Scholar
• Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann. Hepatol.8(Suppl. 1), S4–S8 (2009).
   PubMed Web of Science ®Google Scholar
• Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig. Dis.28(1), 162–168 (2010).
   PubMed Web of Science ®Google Scholar
• Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol.51, 371–379 (2009).
   PubMed Web of Science ®Google Scholar
• Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc.55, 434–438 (1980).
   PubMed Web of Science ®Google Scholar
• Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 Special Conference. J. Hepatol.53, 372–384 (2010).
   PubMed Web of Science ®Google Scholar
• Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int.30, 795–808 (2010).
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology52, 79–104 (2010).
   PubMed Web of Science ®Google Scholar
• Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med.107, 450–455 (1999).
   PubMed Web of Science ®Google Scholar
• Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin. Nutr.18, 353–358 (1999).
   PubMed Web of Science ®Google Scholar
• Lonardo A. Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going? Dig. Dis.17, 80–89 (1999).
   PubMed Web of Science ®Google Scholar
• Lonardo A, Caldwell SH, Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Rev. Endocrinol. Metab.5, 403–423 (2010).
   Google Scholar
• Martínez de Morentin PB, Varela L, Fernø J, Nogueiras R, Diéguez C, López M. Hypothalamic lipotoxicity and the metabolic syndrome. Biochim. Biophys. Acta1801, 350–361 (2010).
   PubMed Web of Science ®Google Scholar
• Day CP., James OF. Steatohepatitis: a tale of two ‘hits’? Gastroenterology114, 842–845 (1998).
   PubMed Web of Science ®Google Scholar
• Daly AK, Ballestri S, Carulli L, Loria P, Day CP. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol.5(2), 253–263 (2011).
   PubMed Web of Science ®Google Scholar
• Vos MB, McClain CJ. Fructose takes a toll. Hepatology50, 1004–1006 (2009).
   PubMed Web of Science ®Google Scholar
• Enjoji M, Nakamuta M. Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease? World J. Gastroenterol.16, 800–803 (2010).
   PubMed Web of Science ®Google Scholar
• Maher JJ. Trunk fat as a determinant of liver disease. Gastroenterology138, 1244–1246 (2010).
   PubMed Web of Science ®Google Scholar
• Church TS, Kuk JL, Ross R, Priest EL, Biltoft E, Blair SN. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology130, 2023–2030 (2006). Erratum in: Gastroenterology132, 466 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology52, 370–381 (2010).
   PubMed Web of Science ®Google Scholar
• Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat. Rev. Gastroenterol. Hepatol.6, 236–247 (2009).
   PubMed Web of Science ®Google Scholar
• Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology140(3), 976–986 (2011).
   PubMed Web of Science ®Google Scholar
• Verdam FJ, Rensen SS, Driessen A, Greve JW, Buurman WA. Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. J. Clin. Gastroenterol.45(2), 149–152 (2011).
   PubMed Web of Science ®Google Scholar
• Aigner E, Strasser M, Haufe H et al. A role for low hepatic copper concentrations in nonalcoholic fatty liver disease. Am. J. Gastroenterol.105, 1978–1985 (2010).
   PubMed Web of Science ®Google Scholar
• Madan K, Bhardwaj P, Thareja S, Gupta SD, Saraya A. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J. Clin. Gastroenterol.40, 930–935 (2006).
   PubMed Web of Science ®Google Scholar
• Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J. Hepatol.50, 1029–1034 (2009).
   PubMed Web of Science ®Google Scholar
• Yoneda M, Nozaki Y, Endo H et al. Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. Dig. Dis. Sci.55, 808–814 (2010).
   PubMed Web of Science ®Google Scholar
• Ratziu V, Giral P, Jacqueminet S et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology135, 100–110 (2008).
   PubMed Web of Science ®Google Scholar
• Nobili V, Manco M, Devito R et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology48, 119–128 (2008).
   PubMed Web of Science ®Google Scholar
• Nobili V, Manco M, Ciampalini P et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin. Ther.30, 1168–1176 (2008).
   PubMed Web of Science ®Google Scholar
• Aithal GP, Thomas JA, Kaye PV et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology135, 1176–1184 (2008).
   PubMed Web of Science ®Google Scholar
• Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology49, 80–86 (2009).
   PubMed Web of Science ®Google Scholar
• Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J. Clin. Gastroenterol.43, 990–994 (2009).
   PubMed Web of Science ®Google Scholar
• Gastaldelli A, Harrison SA, Belfort-Aguilar R et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology50, 1087–1093 (2009).
   PubMed Web of Science ®Google Scholar
• Vilar Gomez E, Rodriguez De Miranda A et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther.30, 999–1009 (2009).
   PubMed Web of Science ®Google Scholar
• Abdelmalek MF, Sanderson SO, Angulo P et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology50, 1818–1826 (2009).
   PubMed Web of Science ®Google Scholar
• Promrat K, Kleiner DE, Niemeier HM et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology51, 121–129 (2010).
   PubMed Web of Science ®Google Scholar
• Ratziu V, Charlotte F, Bernhardt C et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) extension trial. Hepatology51, 445–453 (2010).
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med.362, 1675–1685 (2010).
   PubMed Web of Science ®Google Scholar
• Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol.98, 2485–2490 (2003).
   PubMed Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Heathcote EJ et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology39, 770–778 (2004).
   PubMed Web of Science ®Google Scholar
• Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med.355, 2297–2307 (2006).
   PubMed Web of Science ®Google Scholar
• Dufour JF, Oneta CM, Gonvers JJ et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol.4, 1537–1543 (2006).
   PubMed Web of Science ®Google Scholar
• Zelber-Sagi S, Kessler A, Brazowsky E et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol.4, 639–644 (2006).
   PubMed Web of Science ®Google Scholar
• Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol.15, 942–954 (2009).
   PubMed Web of Science ®Google Scholar
• Leuschner UF, Lindenthal B, Herrmann G et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology52, 472–479 (2010).
   PubMed Web of Science ®Google Scholar
• Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol.96, 519–525 (2001).
   PubMed Web of Science ®Google Scholar
• García-Ruiz I, Rodríguez-Juan C, Díaz-Sanjuán T, Martínez MA, Muñoz-Yagüe T, Solís-Herruzo JA. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. Hepatology46, 414–423 (2007).
   PubMed Web of Science ®Google Scholar
• Caldwell SH, Patrie JT, Brunt EM et al. The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis. Hepatology46, 1101–1107 (2007).
   PubMed Web of Science ®Google Scholar
• Nocito A, Dahm F, Jochum W et al. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology133, 608–618 (2007).
   PubMed Web of Science ®Google Scholar
• Zaldivar MM, Pauels K, von Hundelshausen P et al. CXC chemokine ligand 4 (CXCL4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology51, 1345–1353 (2010).
   PubMed Web of Science ®Google Scholar
• Wouters K, van Gorp PJ, Bieghs V et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology48, 474–486 (2008).
   PubMed Web of Science ®Google Scholar
• Wei Y, Clark SE, Thyfault JP et al. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. Am. J. Pathol.174, 1329–1337 (2009).
   PubMed Web of Science ®Google Scholar
• Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology52, 2206–2215 (2010).
   PubMed Web of Science ®Google Scholar
• Lavine JE, Schwimmer JB, Molleston JP et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp. Clin. Trials31, 62–70 (2010).
   PubMed Web of Science ®Google Scholar
• Lavine JE, Schwimmer JB, Molleston JP et al. Vitamin E, metformin or placebo for treatment of nonalcoholic fatty liver disease in children. Hepatology52(Suppl. 1), A374–A375 (2010).
   Google Scholar
• Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology38, 1008–1017 (2003).
   PubMed Web of Science ®Google Scholar
• Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst. Rev.CD007340 (2010).
   Google Scholar
• Furuya CK Jr, de Oliveira CP, de Mello ES et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J. Gastroenterol. Hepatol.22, 510–514 (2007).
   PubMed Web of Science ®Google Scholar
• Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis, a proposal for grading and staging the histological lesions. Am. J. Gastroenterol.94, 2467–2474 (1999).
   PubMed Web of Science ®Google Scholar
• Promrat K, Lutchman G, Uwaifo GI et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology39, 188–196 (2004).
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology41, 1313–1321 (2005).
   PubMed Web of Science ®Google Scholar